000143453 001__ 143453
000143453 005__ 20240229112553.0
000143453 0247_ $$2doi$$a10.1038/s41572-019-0063-6
000143453 0247_ $$2pmid$$apmid:30765705
000143453 0247_ $$2altmetric$$aaltmetric:55466803
000143453 037__ $$aDKFZ-2019-01041
000143453 041__ $$aeng
000143453 082__ $$a610
000143453 1001_ $$aNorthcott, Paul A$$b0
000143453 245__ $$aMedulloblastoma.
000143453 260__ $$aBasingstoke$$bNature Publishing Group$$c2019
000143453 3367_ $$2DRIVER$$aarticle
000143453 3367_ $$2DataCite$$aOutput Types/Journal article
000143453 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1555402353_21895$$xReview Article
000143453 3367_ $$2BibTeX$$aARTICLE
000143453 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143453 3367_ $$00$$2EndNote$$aJournal Article
000143453 520__ $$aMedulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog (SHH), Group 3 and Group 4), each of which is associated with different genetic alterations, age at onset and prognosis. These subgroups have broadly been incorporated into the WHO classification of central nervous system tumours but still need to be accounted for to appropriately tailor disease risk to therapy intensity and to target therapy to disease biology. In this Primer, the epidemiology (including MB predisposition), molecular pathogenesis and integrative diagnosis taking histomorphology, molecular genetics and imaging into account are reviewed. In addition, management strategies, which encompass surgical resection of the tumour, cranio-spinal irradiation and chemotherapy, are discussed, together with the possibility of focusing more on disease biology and robust molecularly driven patient stratification in future clinical trials.
000143453 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000143453 588__ $$aDataset connected to CrossRef, PubMed,
000143453 7001_ $$aRobinson, Giles W$$b1
000143453 7001_ $$aKratz, Christian P$$b2
000143453 7001_ $$aMabbott, Donald J$$b3
000143453 7001_ $$aPomeroy, Scott L$$b4
000143453 7001_ $$aClifford, Steven C$$b5
000143453 7001_ $$aRutkowski, Stefan$$b6
000143453 7001_ $$aEllison, David W$$b7
000143453 7001_ $$aMalkin, David$$b8
000143453 7001_ $$aTaylor, Michael D$$b9
000143453 7001_ $$aGajjar, Amar$$b10
000143453 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b11$$eLast author$$udkfz
000143453 773__ $$0PERI:(DE-600)2819522-X$$a10.1038/s41572-019-0063-6$$gVol. 5, no. 1, p. 11$$n1$$p11$$tNature reviews / Disease Primers Disease Primers [...]$$v5$$x2056-676X$$y2019
000143453 909CO $$ooai:inrepo02.dkfz.de:143453$$pVDB
000143453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000143453 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000143453 9141_ $$y2019
000143453 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV DIS PRIMERS : 2017
000143453 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143453 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143453 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143453 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143453 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143453 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143453 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNAT REV DIS PRIMERS : 2017
000143453 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000143453 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000143453 980__ $$ajournal
000143453 980__ $$aVDB
000143453 980__ $$aI:(DE-He78)B062-20160331
000143453 980__ $$aI:(DE-He78)L101-20160331
000143453 980__ $$aUNRESTRICTED